BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31114758)

  • 1. Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma.
    Dréau D; Moore LJ; Wu M; Roy LD; Dillion L; Porter T; Puri R; Momin N; Wittrup KD; Mukherjee P
    Front Oncol; 2019; 9():330. PubMed ID: 31114758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early detection of pancreatic cancer in mouse models using a novel antibody, TAB004.
    Wu ST; Williams CD; Grover PA; Moore LJ; Mukherjee P
    PLoS One; 2018; 13(2):e0193260. PubMed ID: 29462213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma.
    Yazdanifar M; Zhou R; Grover P; Williams C; Bose M; Moore LJ; Wu ST; Maher J; Dreau D; Mukherjee AP
    Cells; 2019 Sep; 8(9):. PubMed ID: 31514488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting tumor-associated MUC1 overcomes anoikis-resistance in pancreatic cancer.
    Bose M; Sanders A; De C; Zhou R; Lala P; Shwartz S; Mitra B; Brouwer C; Mukherjee P
    Transl Res; 2023 Mar; 253():41-56. PubMed ID: 36031050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma.
    Tinder TL; Subramani DB; Basu GD; Bradley JM; Schettini J; Million A; Skaar T; Mukherjee P
    J Immunol; 2008 Sep; 181(5):3116-25. PubMed ID: 18713982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis.
    Zhou R; Curry JM; Roy LD; Grover P; Haider J; Moore LJ; Wu ST; Kamesh A; Yazdanifar M; Ahrens WA; Leung T; Mukherjee P
    Oncogene; 2016 Oct; 35(43):5608-5618. PubMed ID: 26804176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A tumor specific antibody to aid breast cancer screening in women with dense breast tissue.
    Roy LD; Dillon LM; Zhou R; Moore LJ; Livasy C; El-Khoury JM; Puri R; Mukherjee P
    Genes Cancer; 2017 Mar; 8(3-4):536-549. PubMed ID: 28680538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer.
    Tholey RM; Lal S; Jimbo M; Burkhart RA; Blanco FF; Cozzitorto JA; Eisenberg JD; Jiang W; Iacobuzio-Donahue CA; Witkiewicz AK; Glbert M; Yeo CJ; Brody JR; Sawicki JA; Winter JM
    Mol Cancer Res; 2015 Mar; 13(3):439-48. PubMed ID: 25336517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of MUC1 Induces Non-Canonical TGF-β Signaling in Pancreatic Ductal Adenocarcinoma.
    Bose M; Grover P; Sanders AJ; Zhou R; Ahmad M; Shwartz S; Lala P; Nath S; Yazdanifar M; Brouwer C; Mukherjee P
    Front Cell Dev Biol; 2022; 10():821875. PubMed ID: 35237602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell programming in pancreatic adenocarcinoma: a review.
    Seo YD; Pillarisetty VG
    Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1.
    Wang K; Zhan Y; Huynh N; Dumesny C; Wang X; Asadi K; Herrmann D; Timpson P; Yang Y; Walsh K; Baldwin GS; Nikfarjam M; He H
    Cancer Lett; 2020 Mar; 472():8-18. PubMed ID: 31857154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
    Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
    Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model.
    Zhang H; Liu C; Zhang F; Geng F; Xia Q; Lu Z; Xu P; Xie Y; Wu H; Yu B; Wu J; Yu X; Kong W
    Vaccine; 2016 May; 34(24):2648-55. PubMed ID: 27113167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-derived interleukin-1 receptor antagonist exhibits immunosuppressive functions and promotes pancreatic cancer.
    Fan YC; Fong YC; Kuo CT; Li CW; Chen WY; Lin JD; Bürtin F; Linnebacher M; Bui QT; Lee KD; Tsai YC
    Cell Biosci; 2023 Aug; 13(1):147. PubMed ID: 37563620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment.
    Mukherjee P; Ginardi AR; Madsen CS; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
    Glycoconj J; 2001; 18(11-12):931-42. PubMed ID: 12820727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
    Kawaoka T; Oka M; Takashima M; Ueno T; Yamamoto K; Yahara N; Yoshino S; Hazama S
    Oncol Rep; 2008 Jul; 20(1):155-63. PubMed ID: 18575732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SMAD4-independent activation of TGF-β signaling by MUC1 in a human pancreatic cancer cell line.
    Grover P; Nath S; Nye MD; Zhou R; Ahmad M; Mukherjee P
    Oncotarget; 2018 Jan; 9(6):6897-6910. PubMed ID: 29467938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.
    Gold DV; Karanjawala Z; Modrak DE; Goldenberg DM; Hruban RH
    Clin Cancer Res; 2007 Dec; 13(24):7380-7. PubMed ID: 18094420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Monoclonal Antibody Targets Mucin1 and Attenuates Growth in Pancreatic Cancer Model.
    Wu G; Maharjan S; Kim D; Kim JN; Park BK; Koh H; Moon K; Lee Y; Kwon HJ
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29987260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.